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Background
Increasing cell specific productivity is still an important
challenge in today’s production of biopharmaceuticals in
mammalian cell cultures. During the last two decades
various efforts were made to achieve higher yields, e.g.
by optimization of process strategies, media develop-
ment or cell line and metabolic engineering. Neverthe-
less, some challenges remain for efficient and applicable
high titer production processes at industrial scale: the
stability of engineered cell lines and the complexity of
stable high-titer production processes as well as the
characterization for regulatory authorities and strategies
for downstream processing [1-3].
We found decreased transcript levels of the de novo
methyltransferase 3a (Dnmt3a) in independent cultiva-
tion processes with increased productivity, i.e. in perfu-
sions under glucose limitation and batch cultivation
upon butyrate treatment. To prove the hypothesis that
reduced transcript levels of Dnmt3a is responsible for
an increase in productivity, we investigated the influence
of RNAi-mediated knockdown of Dnmt3a in recombi-
nant CHO cells on cell growth, viability and cellular and
process productivity.
Materials and methods
Cultivations of an IgG1-producing CHO-XL99 clone
(provided by Dr. Jeff Hou, AIBN, University of Queens-
land) and the anti-IL-8 producing CHO DP-12 clone
#1934 (ATCC CRL-12445) were performed in custo-
mized chemically defined animal-component free media
(Xell AG) in perfusion and batch mode. Samples for
viable cell densities and viabilities (automated cell count-
ing system CEDEX, Roche Diagnostics) and for determina-
tion of IgG1 antibody concentrations (Protein A
(Invitrogen) HPLC, using CHO DP-12 standards) were
taken daily. Western blots were performed using Dnmt3a
rabbit monoclonal antibody (D23G1, Cell Signaling) and
AffiniPure goat anti-rabbit IgG (Jackson Immuno Research
Laboratories).
To explore the influence of decreased Dnmt3a levels
in antibody producing recombinant CHO cell lines,
three different siRNAs and one scrambled control were
designed (shRNA Sequence Designer (Clontech), siRNA
Wizard (Invivogen)). After cloning each siRNA into the
pcDNA 3.1 vector (Life Technologies) and transforma-
tion of TOP10 E.coli cells, the CHO-XL99 cells were
transfected using the nucleofector (Nucleofector™ 2b,
Lonza) and nucleofector kit V (Lonza). Transfected cells
were grown in parallel for 24 h with an untransfected
and a scrambled control in customized chemically
defined animal-component free media (Xell AG). Sam-
ples for analysis of cell growth and viability as well as
for monoclonal antibody (IgG1) were taken before and
24 h post-transfection; cell specific productivities were
calculated.
Results
After 24 days of cultivation cell specific productivity
started to increase in late, glucose-limited phase of
CHO-XL99 clone perfusion (data not shown). Corre-
sponding to this, the expression level of Dnmt3a
decreased (Figure 1A). Furthermore, upon butyrate
treatment cell specific productivity increased in different
CHO cell lines and process modi with decreased
Dnmt3a expression levels (data not shown).
Based on this, we hypothesized that reduced expression
of Dnmt3a is responsible for an increase in productivity
under glucose limitation as well as upon butyrate
treatment.
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RNAi mediated transient silencing of the de novo
methyltransferase Dnmt3a led to enhanced cell specific
productivity of up to 4.95 pg/(cell × d) compared to the
control culture (0.23 pg/(cell × d)) and the scrambled
control (0.11 pg/(cell × d)) (Figure 1B). Although a
strong decrease in cellular viability was observed, pro-
duct titers were increased by 31-201 % (Figure 1B).
Besides enhanced productivity, transient transfections
showed strong negative impact on viable cell densities
and viabilities of CHO-XL99 cells. Viable cell densities
decreased from 5.3 × 105 cells/mL to 1.8 × 105 cells/mL
(siRNA 1), 1.9 × 105 cells/mL (siRNA 2) and 2.8 × 105
cells/mL (siRNA 2), respectively, 24 h post-transfection
(Figure 1C). Viabilities dropped from an initial value of
96 % to 55% (siRNA 2), 49 % (siRNA 3) and 44 %
(siRNA 1), respectively (Figure 1 D). The control culture
and transfection with scrambled control remained unaf-
fected in all cases (Figure 1B-D).
These results indicated that a reduced expression of
Dnmt3a could be responsible for enhanced productivity
but also results in a strong decrease in viability and cell
density.
Conclusions
In this study we found that both glucose limitation and
butyrate treatment enhance cell specific productivity in
CHO DP-12 and CHO-XL99 cells. Moreover, a correla-
tion between enhanced monoclonal antibody production
and the expression level of the de novo methyltransfer-
ase 3a could be observed.
To further explore this phenomenon, we designed
several siRNAs and transfected CHO-XL99 cells transi-
ently. This transient knockdown of Dnmt3a enhanced
productivity but negatively impacted growth. The
increase in monoclonal antibody production might be
due to DNA methylation events. To overcome negative
side effects on cellular viability and cell growth, stable
cell lines using an inducible RNAi system are under
preparation. These stable cell lines with inducible
knockdown of Dnmt3a will offer the opportunity to
Figure 1 Correlation between enhanced antibody production and decreased Dnmt3a expression level. (a) Correlation between cell
specific productivity of a CHO-XL99 clone in cultivation time course of perfusion and Dnmt3a protein expression level (n = 4, protein expression
levels were normalized to t6). (b) Average monoclonal antibody concentrations of transient transfected CHO-XL99 cells and untransfected
control, n = 2. Numbers above bars represent cell specific productivities [pg/(cell × d)] within 24 h. (c) Average viable cell densities of
transfected CHO-XL99 cells and untransfected control. (d) Average viabilities of transfected CHO-XL99 cells and untransfected control.
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have a more detailed view on the mechanisms of
enhanced monoclonal antibody production.
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